Ulisse Biomed S.p.A. (BIT:UBM)

Ulisse Biomed Statistics

Total Valuation

Ulisse Biomed has a market cap or net worth of EUR 24.48 million. The enterprise value is 24.43 million.

Market Cap	24.48M
Enterprise Value	24.43M

Important Dates

The next estimated earnings date is Tuesday, December 30, 2025.

Earnings Date	Dec 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Ulisse Biomed has 24.48 million shares outstanding. The number of shares has increased by 12.28% in one year.

Current Share Class	24.48M
Shares Outstanding	24.48M
Shares Change (YoY)	+12.28%
Shares Change (QoQ)	-9.86%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	26.44
PB Ratio	1.15
P/TBV Ratio	8.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.61
EV / Sales	26.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.17

Financial Position

The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.05.

Current Ratio	2.53
Quick Ratio	1.51
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.38
Interest Coverage	-337.77

Financial Efficiency

Return on equity (ROE) is -23.06% and return on invested capital (ROIC) is -14.48%.

Return on Equity (ROE)	-23.06%
Return on Assets (ROA)	-12.80%
Return on Invested Capital (ROIC)	-14.48%
Return on Capital Employed (ROCE)	-23.61%
Revenue Per Employee	51,437
Profits Per Employee	-294,544
Employee Count	22
Asset Turnover	0.03
Inventory Turnover	0.91

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +8.46% in the last 52 weeks. The beta is 0.82, so Ulisse Biomed's price volatility has been lower than the market average.

Beta (5Y)	0.82
52-Week Price Change	+8.46%
50-Day Moving Average	1.01
200-Day Moving Average	0.85
Relative Strength Index (RSI)	43.02
Average Volume (20 Days)	102,200

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ulisse Biomed had revenue of EUR 925,866 and -5.30 million in losses. Loss per share was -0.22.

Revenue	925,866
Gross Profit	-804,442
Operating Income	-5.49M
Pretax Income	-5.30M
Net Income	-5.30M
EBITDA	-1.77M
EBIT	-5.49M
Loss Per Share	-0.22

Balance Sheet

The company has 1.06 million in cash and 1.00 million in debt, giving a net cash position of 57,510 or 0.00 per share.

Cash & Cash Equivalents	1.06M
Total Debt	1.00M
Net Cash	57,510
Net Cash Per Share	0.00
Equity (Book Value)	21.24M
Book Value Per Share	0.87
Working Capital	2.74M

Cash Flow

In the last 12 months, operating cash flow was -2.65 million and capital expenditures -12,616, giving a free cash flow of -2.66 million.

Operating Cash Flow	-2.65M
Capital Expenditures	-12,616
Free Cash Flow	-2.66M
FCF Per Share	-0.11

Margins

Gross Margin	-86.89%
Operating Margin	-593.23%
Pretax Margin	-572.63%
Profit Margin	n/a
EBITDA Margin	-191.50%
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Ulisse Biomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.28%
Shareholder Yield	-12.28%
Earnings Yield	-21.66%
FCF Yield	-10.88%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ulisse Biomed has an Altman Z-Score of 1.5 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.5
Piotroski F-Score	4